Novocure NVCR 深 沪
已收盘 08-14 16:00:00 美东时间
16.95
-0.430
-2.47%
华盛通- 最 高17.23
- 今 开17.23
- 成交量 68.13万股
- 最 低 16.80
- 昨 收 17.38
- 总市值 197.38万
- 52周最高 21.4506
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 9.82
- 委 比 11.06%
- 总股本 0.00亿
- 历史最高 232.76
- 量 比 0.70
- 振 幅 2.47%
- 历史最低 5.95
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高120美元！大小摩等7家大行集体上调英特尔目标价；汇丰首予SpaceX"持有"评级，目标价115美元
今日重点评级关注：HC Wainwright & Co.：维持居里"买入"评级，目标价从17美元升至43美元；花旗：维持Klaviyo"买入"评级，目标价从31美元升至34美元
07-27 14:02
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure Ltd. (NASDAQ:NVCR) shares rose in Friday’s premarket session before dropping after the company raised its full-year 2026 revenue outlook and reported second-quarter earnings and sales above analyst expectations. The stock closed Thursday at $19.99, up 28.39%. • NovoCure stock is among today...
07-24 23:08
美股牛股 | 绩优股齐升！钢铁公司CLF劲升16%，Q2净亏损同比大幅收窄七成；医药股MEDP升逾14%
绩优股齐升！钢铁公司CLF劲升16%，Q2净亏损同比大幅收窄七成；医药股MEDP升逾14%，Q2净利大增且积压订单强劲；IMAX升近12%，Q2利润率近5成，维持全年票房目标>>
07-24 18:56
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $46 to $52.
07-24 01:50
财报速睇 | Novocure 2026财年Q2营收1.84亿美元，同比增长15.6%；归母净利润亏损0.16亿美元，同比亏损缩窄61.0%
华盛资讯7月23日讯，Novocure公布2026财年Q2业绩，公司Q2营收1.84亿美元，同比增长15.6%，归母净利润亏损0.16亿美元，同比亏损缩窄61.0%。
07-23 19:23
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report quarterly earnings at $0.78 per share on revenue of $123.06 million. • Infosys (NYSE...
07-23 19:11
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est
NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.000 million-$725.000 million vs $708.743 million estimate.
07-23 19:01
NovoCure Q2 EPS $(0.13) Beats $(0.33) Estimate, Sales $183.584M Beat $172.437M Estimate
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.33) by 60.61 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $183.584 million whic...
07-23 19:01
